alexa The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma


Chemotherapy: Open Access

Author(s): Matthew Howell, Juan W Valle

Abstract Share this page

Cholangiocarcinomas are rare cancers arising from the epithelia of the biliary tract. The only prospect of curative therapy is with surgery. However, relapse rates are high with five-year survival rates typically around 20–30%. Involved resection margins and spread to local lymph nodes are associated with a higher risk of relapse. Such poor outcomes provide a rationale for adjuvant strategies to improve survival. However, there is little randomised data to support the use of adjuvant therapy; the available evidence base is based mostly on retrospective case series and results are often conflicting. This review evaluates the available evidence. Adjuvant therapy may be considered on an individual patient basis after discussion of the limitations of our knowledge. The results of prospective, randomised clinical trials of adjuvant therapy are eagerly awaited. Progress will require collaboration of basic science and clinical oncology and the execution of well-designed clinical trials.

  • To read the full article Visit
  • Subscription
This article was published in Clinical gastroenterology and referenced in Chemotherapy: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version